Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Post by stockbond007on Dec 16, 2010 8:22pm
526 Views
Post# 17859459

New release the word is out

New release the word is out
The word is out and this is just the beginning. Today was cdn investors next few days investors from the USA
will be comming in.

https://www.stockhouse.com/pfolio.aspx?frame=/pfolio_V2.asp%3F%26portid%3D1301688%26lang%3D


This is from the new release:

"BELLUS Health's most advanced pharmaceutical candidate is KIACTA (eprodisate) to treat Amyloid A (AA) amyloidosis, a disease marked by an abnormal accumulation of certain proteins that can cause organ dysfunction, organ failure, and even death. In December 2010, KIACTA entered a confirmatory Phase III trial funded by Celtic Therapeutics, a global private equity firm.

-- The Company's pharmaceutical pipeline also includes NRM8499, a prodrug for Alzheimer's disease (AD) that entered a Phase I trial in March 2010.

-- Additionally, through a wholly owned subsidiary, OVOS Natural Health Inc., the Company markets a clinically tested nutraceutical called VIVIMIND (tramiprosate/homotaurine) to protect memory function. VIVIMIND is available online and has been granted approval for sale in Canada, Italy, and Spain. "

Incredible potential

Do your dd

SB

Bullboard Posts